Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scholar Rock HoldingFRA:2QK -1.50%34 3-1 Month Momentum % is 1.00% as of Sep. 02, 2026. GuruFocus rates FRA:2QK with a GF Score™ of 34/100 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,386 Biotechnology companies, Scholar Rock Holding ranks better than 67.6% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-02), Scholar Rock Holding's 3-1 Month Momentum % is 1.00%.
The industry rank for Scholar Rock Holding's 3-1 Month Momentum % or its related term are showing as below:
FRA:2QK's 3-1 Month Momentum % is ranked better than 67.6% of 1386
companies
in the Biotechnology industry
Industry Median: -9.25
vs FRA:2QK: 1.00
Scholar Rock Holding (FRA:2QK) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Scholar Rock Holding 3-1 Month Momentum % Related Terms
FRA:2QK vs CAI, RYTM, CGON: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Scholar Rock Holding's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scholar Rock Holding 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Scholar Rock Holding's 3-1 Month Momentum % falls into.
Scholar Rock Holding (FRA:2QK) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scholar Rock Holding (FRA:2QK) has a 3-1 Month Momentum % of 1.00% as of Sep. 02, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Scholar Rock Holding and its competitors. According to the industry distribution chart, Scholar Rock Holding ranks #449 out of 1386 companies in the Biotechnology industry, placing it in the top 32.4%.
Is Scholar Rock Holding's 3-1 Month Momentum % too high?
Scholar Rock Holding's current 3-1 Month Momentum % is 1.00%. Based on the distribution chart, Scholar Rock Holding ranks #449 out of 1386 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Scholar Rock Holding has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's 3-1 Month Momentum % compare to CAI and RYTM?
According to the Biotechnology industry distribution chart, Scholar Rock Holding ranks #449 out of 1386 companies for 3-1 Month Momentum %. This puts Scholar Rock Holding in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Scholar Rock Holding and its competitors. Scholar Rock Holding's current 3-1 Month Momentum % is 1.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Based on GuruFocus' analysis, Scholar Rock Holding (FRA:2QK) is currently considered Significantly Overvalued. The current 3-1 Month Momentum % is 1.00%. Scholar Rock Holding's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current 3-1 Month Momentum % is 1.00% as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
34GF Score
Get the complete analysis for FRA:2QK
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QK has been successfully added to your 
